Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immunomodulatory approaches to the management of chronic urticaria: An immune-mediated inflammatory disease

Immunomodulatory approaches to the management of chronic urticaria: An immune-mediated... Although commonly encountered in clinical practice, chronic urticaria (CU) remains difficult to treat. In contrast to acute urticaria, neither exogenous triggers nor specific immunoglobulin E are identified in most chronic cases. A body of evidence suggests that CU is represented within the spectrum of immune-mediated inflammatory diseases (IMID). Our understanding of the CU disease pathogenesis now recognizes a role for T cells, B cells, and autoantibodies, and intrinsic abnormalities of histamine-releasing effector cells, thus providing new targets of intervention beyond the current mainstay of often inadequate symptomatic treatment directed against histamine receptors and steroids, with their attendant morbidities. Agents previously used to treat other autoimmune and inflammatory diseases have demonstrated efficacy in CU. Newer biologic and nonbiologic immunomodulatory agents approved for other indications and in clinical development provide potential options for this often severe disease. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Allergy and Asthma Reports Springer Journals

Immunomodulatory approaches to the management of chronic urticaria: An immune-mediated inflammatory disease

Bingham, Clifton
Current Allergy and Asthma Reports , Volume 8 (4) – Oct 11, 2008
Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/immunomodulatory-approaches-to-the-management-of-chronic-urticaria-an-WPHqH1wzEN

References (74)

Publisher
Springer Journals
Copyright
Copyright © 2008 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Otorhinolaryngology; Pneumology/Respiratory System; Allergology
ISSN
1529-7322
eISSN
1534-6315
DOI
10.1007/s11882-008-0046-2
Publisher site
See Article on Publisher Site

Abstract

Although commonly encountered in clinical practice, chronic urticaria (CU) remains difficult to treat. In contrast to acute urticaria, neither exogenous triggers nor specific immunoglobulin E are identified in most chronic cases. A body of evidence suggests that CU is represented within the spectrum of immune-mediated inflammatory diseases (IMID). Our understanding of the CU disease pathogenesis now recognizes a role for T cells, B cells, and autoantibodies, and intrinsic abnormalities of histamine-releasing effector cells, thus providing new targets of intervention beyond the current mainstay of often inadequate symptomatic treatment directed against histamine receptors and steroids, with their attendant morbidities. Agents previously used to treat other autoimmune and inflammatory diseases have demonstrated efficacy in CU. Newer biologic and nonbiologic immunomodulatory agents approved for other indications and in clinical development provide potential options for this often severe disease.

Journal

Current Allergy and Asthma Reports – Springer Journals

Published: Oct 11, 2008

There are no references for this article.